Stockscreener 앱 받기
40.37
5.21%
2.00
Maze Therapeutics Inc 주식(MAZE)의 최신 뉴스
Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
BERNSTEIN HAROLD Insider Trades - Nasdaq
Maze Therapeutics (NASDAQ:MAZE) Stock Price Down 4.9% – Here’s Why - Defense World
Aug Patterns: How Maze Therapeutics Inc stock compares to market leadersWeekly Trade Summary & Free High Accuracy Swing Entry Alerts - moha.gov.vn
Maze Therapeutics (NASDAQ:MAZE) Trading Down 4.9%Here's Why - MarketBeat
Amy Bachrodt Sells 5,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - Defense World
Amy Bachrodt Sells 10,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - Defense World
Harold Bernstein Sells 45,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - Defense World
Atul Dandekar Sells 72,400 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - Defense World
Maze Therapeutics SVP, finance sells $606k in shares By Investing.com - Investing.com Australia
Maze Therapeutics (NASDAQ:MAZE) CMO Sells $1,825,200.00 in Stock - MarketBeat
Insider Selling: Maze Therapeutics (NASDAQ:MAZE) SVP Sells 5,000 Shares of Stock - MarketBeat
Maze Therapeutics SVP, finance sells $606k in shares - Investing.com
Maze Therapeutics Insider Sold Shares Worth $1,825,355, According to a Recent SEC Filing - MarketScreener
Maze Therapeutics Executives Engage in Significant Stock Transactions - TradingView — Track All Markets
Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
BACHRODT AMY Insider Trades - Nasdaq
Growth Recap: Is Maze Therapeutics Inc stock trading at a premium valuationEarnings Overview Summary & Free Real-Time Volume Trigger Notifications - moha.gov.vn
How Maze Therapeutics Inc. stock benefits from tech adoptionMACD Histogram Signals & Free Fast Track Wealth Growth - bollywoodhelpline.com
New way to pay for at‑home AI neurorehab aims to widen access - Stock Titan
We Think Maze Therapeutics (NASDAQ:MAZE) Can Easily Afford To Drive Business Growth - Yahoo Finance
FY2025 Earnings Estimate for MAZE Issued By Lifesci Capital - MarketBeat
Maze Therapeutics price target raised to $46 from $34 at Guggenheim - MSN
Fundamentals Check: How Maze Therapeutics Inc. stock benefits from tech adoptionWeekly Stock Recap & Expert Approved Trade Ideas - Улправда
Maze Therapeutics (NASDAQ:MAZE) Stock Rating Upgraded by Lifesci Capital - Defense World
Guggenheim raises Maze Therapeutics stock price target to $46 on CKD program - Investing.com Canada
What sentiment indicators say about Maze Therapeutics Inc. stockEarnings Risk Summary & Community Shared Stock Ideas - DonanımHaber
Lifesci Capital Upgrades Maze Therapeutics (NASDAQ:MAZE) to Strong-Buy - MarketBeat
What dividend safety score for Maze Therapeutics Inc. stockWeekly Trade Analysis & Weekly Setup with High ROI Potential - Улправда
Leerink Partners raises Maze Therapeutics stock price target to $50 on AMKD study - Investing.com Canada
Edison Issues Report on MindMaze Therapeutics (MMTX) - TMX Newsfile
Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics - Yahoo Finance
Frazier Life Sciences Management L.P. Buys 438,274 Shares of Maze Therapeutics, Inc. $MAZE - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Upgraded at Wall Street Zen - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Stock Price Down 6.2%Time to Sell? - MarketBeat
CW Advisors LLC Purchases Shares of 30,235 Maze Therapeutics, Inc. $MAZE - MarketBeat
Investment Report: How Maze Therapeutics Inc stock benefits from tech adoptionJuly 2025 Market Mood & Accurate Buy Signal Alerts - BỘ NỘI VỤ
Maze Therapeutics (MAZE) Price Target Increased by 11.37% to 44.12 - Nasdaq
Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Recommendation of “Buy” by Brokerages - Defense World
Wells Fargo Initiates Coverage of Maze Therapeutics (MAZE) with Overweight Recommendation - Nasdaq
Maze Therapeutics (NASDAQ:MAZE) Sets New 52-Week HighTime to Buy? - MarketBeat
Maze Therapeutics stock price target raised to $60 from $50 at H.C. Wainwright - Investing.com Canada
A significant driver of top-line growth: Maze Therapeutics Inc (MAZE) - setenews.com
MAZE Crosses Above Average Analyst Target - Nasdaq
Maze Therapeutics stock rating initiated at Overweight by Wells Fargo - Investing.com Canada
HC Wainwright & Co. Maintains Maze Therapeutics (MAZE) Buy Recommendation - Nasdaq
MAZE: Pivotal APOL1 kidney disease data and new phase 2 studies are set for 2026, driving major growth - TradingView
MAZE: Pivotal APOL1 kidney disease data and new phase 2 studies are set for 2026 - TradingView
Maze Therapeutics (MAZE) Stock Analysis Report | Financials & Insights - Benzinga
Virtus Investment Advisers LLC Invests $85,000 in Maze Therapeutics, Inc. $MAZE - MarketBeat
Ensign Peak Advisors Inc Buys Shares of 18,539 Maze Therapeutics, Inc. $MAZE - Defense World
Maze Therapeutics stock hugs flat line following $140M IPO - MSN
Technical Analysis of Maze Therapeutics, Inc. (NASDAQ:MAZE) - TradingView
28.63%
자본화:
|
볼륨(24시간):